Business Description
Enlivex Therapeutics Ltd
ISIN : IL0011319527
Description
Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 32.03 | |||||
| Equity-to-Asset | 0.89 | |||||
| Debt-to-Equity | 0.03 | |||||
| Debt-to-EBITDA | -0.05 | |||||
| Piotroski F-Score | 3/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -22 | |||||
| 3-Year EPS without NRI Growth Rate | -20.2 | |||||
| 3-Year FCF Growth Rate | -11.9 | |||||
| 3-Year Book Growth Rate | -12.7 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 21.67 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 54.65 | |||||
| 9-Day RSI | 53.48 | |||||
| 14-Day RSI | 51.99 | |||||
| 6-1 Month Momentum % | -10.46 | |||||
| 12-1 Month Momentum % | -63.85 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 9.71 | |||||
| Quick Ratio | 9.71 | |||||
| Cash Ratio | 8.78 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -8.4 | |||||
| Shareholder Yield % | -5.38 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -62.75 | |||||
| ROA % | -53.63 | |||||
| ROIC % | -240.81 | |||||
| ROC (Joel Greenblatt) % | -344.71 | |||||
| ROCE % | -51.46 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 1.03 | |||||
| Price-to-Tangible-Book | 1.03 | |||||
| EV-to-EBIT | -0.14 | |||||
| EV-to-EBITDA | -0.14 | |||||
| EV-to-FCF | -0.26 | |||||
| Price-to-Net-Current-Asset-Value | 1.15 | |||||
| Price-to-Net-Cash | 1.29 | |||||
| Earnings Yield (Greenblatt) % | -734.72 | |||||
| FCF Yield % | -54.78 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Enlivex Therapeutics Ltd Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ₪) | |||
| EPS (TTM) (₪) | -3.594 | ||
| Beta | 0 | ||
| Volatility % | 74.79 | ||
| 14-Day RSI | 51.99 | ||
| 14-Day ATR (₪) | 0.289486 | ||
| 20-Day SMA (₪) | 4.4 | ||
| 12-1 Month Momentum % | -63.85 | ||
| 52-Week Range (₪) | 3.5 - 16 | ||
| Shares Outstanding (Mil) | 21.99 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Enlivex Therapeutics Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Enlivex Therapeutics Ltd Stock Events
| Event | Date | Price(₪) | ||
|---|---|---|---|---|
| No Event Data | ||||
Enlivex Therapeutics Ltd Frequently Asked Questions
What is Enlivex Therapeutics Ltd(XTAE:ENLV)'s stock price today?
The current price of XTAE:ENLV is ₪4.49. The 52 week high of XTAE:ENLV is ₪16.00 and 52 week low is ₪3.50.
When is next earnings date of Enlivex Therapeutics Ltd(XTAE:ENLV)?
The next earnings date of Enlivex Therapeutics Ltd(XTAE:ENLV) is 2025-01-17 Est..
Does Enlivex Therapeutics Ltd(XTAE:ENLV) pay dividends? If so, how much?
Enlivex Therapeutics Ltd(XTAE:ENLV) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers